NovaGo Therapeutics focuses on two regeneration promoting therapeutics aimed at restoring nerve fibre connections in acute spinal cord injury(SCI) and retinal vasculature in diabetic retinopathy(DR), Ph1b clinical trial for SCI was started in Dec 2024. Ph1b studies in DR are planned for end 2025.

Location
Canton
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2015
  • Number of employees in Switzerland
    1-9
Key business

You may also be interested in